JP2012502919A - 進行型多発性硬化症の治療方法 - Google Patents

進行型多発性硬化症の治療方法 Download PDF

Info

Publication number
JP2012502919A
JP2012502919A JP2011527065A JP2011527065A JP2012502919A JP 2012502919 A JP2012502919 A JP 2012502919A JP 2011527065 A JP2011527065 A JP 2011527065A JP 2011527065 A JP2011527065 A JP 2011527065A JP 2012502919 A JP2012502919 A JP 2012502919A
Authority
JP
Japan
Prior art keywords
antibody
patient
multiple sclerosis
treatment
edss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011527065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502919A5 (cg-RX-API-DMAC7.html
Inventor
クレイグ スミス，
ピーター， エス． チン，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012502919(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2012502919A publication Critical patent/JP2012502919A/ja
Publication of JP2012502919A5 publication Critical patent/JP2012502919A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Theoretical Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
JP2011527065A 2008-09-16 2009-09-16 進行型多発性硬化症の治療方法 Withdrawn JP2012502919A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9746408P 2008-09-16 2008-09-16
US61/097,464 2008-09-16
PCT/US2009/057151 WO2010033587A2 (en) 2008-09-16 2009-09-16 Methods for treating progressive multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014151366A Division JP2015007057A (ja) 2008-09-16 2014-07-25 進行型多発性硬化症の治療方法

Publications (2)

Publication Number Publication Date
JP2012502919A true JP2012502919A (ja) 2012-02-02
JP2012502919A5 JP2012502919A5 (cg-RX-API-DMAC7.html) 2012-11-01

Family

ID=41571287

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011527065A Withdrawn JP2012502919A (ja) 2008-09-16 2009-09-16 進行型多発性硬化症の治療方法
JP2014151366A Withdrawn JP2015007057A (ja) 2008-09-16 2014-07-25 進行型多発性硬化症の治療方法
JP2016022890A Active JP6306070B2 (ja) 2008-09-16 2016-02-09 進行型多発性硬化症の治療方法
JP2018040425A Pending JP2018127461A (ja) 2008-09-16 2018-03-07 進行型多発性硬化症の治療方法
JP2019173818A Pending JP2020023507A (ja) 2008-09-16 2019-09-25 進行型多発性硬化症の治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014151366A Withdrawn JP2015007057A (ja) 2008-09-16 2014-07-25 進行型多発性硬化症の治療方法
JP2016022890A Active JP6306070B2 (ja) 2008-09-16 2016-02-09 進行型多発性硬化症の治療方法
JP2018040425A Pending JP2018127461A (ja) 2008-09-16 2018-03-07 進行型多発性硬化症の治療方法
JP2019173818A Pending JP2020023507A (ja) 2008-09-16 2019-09-25 進行型多発性硬化症の治療方法

Country Status (25)

Country Link
US (12) US20100158903A1 (cg-RX-API-DMAC7.html)
EP (4) EP2331132A2 (cg-RX-API-DMAC7.html)
JP (5) JP2012502919A (cg-RX-API-DMAC7.html)
CN (2) CN104826107B (cg-RX-API-DMAC7.html)
AR (2) AR073295A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009293363B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0918604A2 (cg-RX-API-DMAC7.html)
CA (1) CA2737074C (cg-RX-API-DMAC7.html)
CL (1) CL2011000553A1 (cg-RX-API-DMAC7.html)
DK (2) DK3095463T3 (cg-RX-API-DMAC7.html)
EA (1) EA034369B1 (cg-RX-API-DMAC7.html)
ES (2) ES2988466T3 (cg-RX-API-DMAC7.html)
FI (1) FI3747464T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241143T1 (cg-RX-API-DMAC7.html)
HU (2) HUE067882T2 (cg-RX-API-DMAC7.html)
IL (3) IL211710A0 (cg-RX-API-DMAC7.html)
LT (2) LT3747464T (cg-RX-API-DMAC7.html)
MX (2) MX2011002627A (cg-RX-API-DMAC7.html)
PL (2) PL3095463T3 (cg-RX-API-DMAC7.html)
PT (2) PT3095463T (cg-RX-API-DMAC7.html)
SG (2) SG10201913368UA (cg-RX-API-DMAC7.html)
SI (2) SI3095463T1 (cg-RX-API-DMAC7.html)
TW (2) TW201014605A (cg-RX-API-DMAC7.html)
WO (1) WO2010033587A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201101854B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023123521A (ja) * 2015-10-06 2023-09-05 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056312A2 (en) * 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
ZA200610158B (en) * 2004-06-04 2008-07-30 Genentech Inc Method for treating multiple sclerosis
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CA2771203C (en) 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
ES2558556T3 (es) * 2010-03-03 2016-02-05 Teva Pharmaceutical Industries Ltd. Tratamiento de nefritis lúpica usando laquinimod
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014506258A (ja) * 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規使用
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
EP2530088A1 (en) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Means and methods for diagnosing and treating multiple sclerosis
BR112014002095A2 (pt) * 2011-07-28 2017-02-21 Teva Pharma tratamento de esclerose múltipla com combinação de laquinimod e acetato de glatiramer
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
TW201345527A (zh) 2012-02-03 2013-11-16 Teva Pharma 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途
KR20140148411A (ko) * 2012-03-12 2014-12-31 메디뮨 엘엘씨 항-cd19 항체를 이용한 다발성 경화증의 치료
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
AU2013329348A1 (en) * 2012-10-12 2015-05-28 Teva Pharmaceutical Industries Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
ITFI20120238A1 (it) * 2012-11-06 2014-05-07 Casalife S R L Dispositivo e apparato di misura e monitoraggio ambientale domestico
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
ES2752021T3 (es) 2013-02-01 2020-04-02 Glialogix Inc Composiciones y métodos para el tratamiento de enfermedades neurodegenerativas y otras enfermedades
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
EA201591699A1 (ru) 2013-03-14 2016-02-29 Тева Фармасьютикал Индастриз Лтд. Кристаллы лаквинимода натрия и улучшенный способ их производства
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
US20150306088A1 (en) 2014-04-29 2015-10-29 Teva Pharmaceutical Industries, Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
MY193078A (en) 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
CN108137697A (zh) 2015-10-02 2018-06-08 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2016008541A (es) * 2015-10-06 2017-12-26 Genentech Inc Metodo para tratar esclerosis multiple.
RU2757961C2 (ru) * 2015-10-06 2021-10-25 Дженентек, Инк. Способ лечения рассеянного склероза
JP6851391B2 (ja) 2016-08-15 2021-03-31 ノバルティス アーゲー オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (da) 2016-08-31 2023-07-31 Mapi Pharma Ltd Depotsystemer, der omfatter glatirameracetat
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
EP3720880A1 (en) * 2017-12-05 2020-10-14 Mabion SA Combination therapy of multiple sclerosis comprising a cd20 ligand
EP3864053B1 (en) * 2019-09-11 2023-07-05 Novartis AG Treatment of rms by switching therapy
US20220064320A1 (en) * 2020-08-14 2022-03-03 Hoffmann-La Roche Inc. Methods for treating multiple sclerosis with ocrelizumab

Family Cites Families (251)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61945A (en) 1867-02-12 James maeshall
US2229275A (en) 1939-07-15 1941-01-21 M J B Company Key for cans
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
RU2138512C1 (ru) 1989-03-21 1999-09-27 Дзе Иммюн Риспонз Корпорейшн Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
AU652540B2 (en) 1989-07-19 1994-09-01 Xoma Corporation T cell receptor peptides as therapeutics for autoimmune and malignant disease
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2132091C (en) 1992-04-03 2008-09-16 Kyung J. Kim Antibodies to alphavbeta3 integrin
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0669986B1 (en) 1992-11-13 2003-04-09 Idec Pharmaceuticals Corporation Fully impaired consensus kozac sequences for mammalian expression
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
SI0950067T1 (sl) 1996-11-27 2007-12-31 Genentech Inc Afinitetno čiščenje polipeptida na proteinskemA matriksu
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
DE69907439T3 (de) 1998-05-06 2014-01-02 Genentech, Inc. Reinigung von proteinen durch ionenaustauschchromatographie
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
WO2000009160A1 (en) 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
GB9821061D0 (en) * 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
JP2002529429A (ja) 1998-11-09 2002-09-10 アイデック・ファーマシューティカルズ・コーポレイション Ｂｍｔまたはｐｂｓｃ移植を受ける患者のキメラ化抗ｃｄ２０抗体による治療。
CN1679934B (zh) 1998-11-09 2012-09-05 生物基因Idec公司 使用抗cd20嵌合抗体治疗循环肿瘤细胞相关的血液恶性肿瘤
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6596657B1 (en) * 1999-02-17 2003-07-22 Poly-Med, Inc. Antimicrobial fabrics
US6383276B1 (en) 1999-03-12 2002-05-07 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
CN100358577C (zh) 1999-05-07 2008-01-02 杰南技术公司 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de) 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
HK1047702A1 (zh) 1999-07-12 2003-03-07 Genentech Inc. 用与cd20结合的拮抗剂阻断对外来抗原的免疫应答
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
CN101259270A (zh) 1999-08-11 2008-09-10 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
US6238302B1 (en) * 1999-09-03 2001-05-29 Callaway Golf Company Golf club head with an insert having integral tabs
US20030039659A1 (en) 1999-09-24 2003-02-27 Mccormick Alison A. Self antigen vaccines for treating B cell lymphomas and other cancers
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
RU2305561C2 (ru) 1999-11-08 2007-09-10 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием антител против cd40l в комбинации с антителами против cd20 и/или химиотерапией и лучевой терапией
CA2400040A1 (en) 2000-02-25 2001-08-30 Immunex Corporation Integrin antagonists
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
US20020009427A1 (en) 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma
KR20020091170A (ko) 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
ATE375330T1 (de) 2000-04-17 2007-10-15 Ucb Pharma Sa Enamin-derivate als zell-adhäsionsmoleküle
KR20030016250A (ko) 2000-04-25 2003-02-26 아이덱 파마슈티칼즈 코포레이션 중추신경계 림프종 치료용 리툭시맵의 초내 투여
WO2001097858A2 (en) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
ATE440618T1 (de) 2000-06-22 2009-09-15 Univ Iowa Res Found Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
AU6461201A (en) 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CZ302653B6 (cs) 2000-08-18 2011-08-17 Ajinomoto Co., Inc. Fenylalaninové deriváty, alfa-4-integrinový antagonist, terapeutické cinidlo nebo preventivní cinidlo a farmaceutický prostredek obsahující tyto deriváty
EP1311549A2 (en) 2000-08-22 2003-05-21 Micromet AG Composition for the elimination of autoreactive b-cells
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
JP4895067B2 (ja) 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002213357A1 (en) 2000-10-20 2002-05-06 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
IL157142A0 (en) 2001-01-29 2004-02-08 Idec Pharma Corp Modified antibodies and methods of use
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
DE60239931D1 (de) 2001-04-02 2011-06-16 Genentech Inc Kombinationstherapie
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
WO2002102312A2 (en) 2001-06-14 2002-12-27 Intermune, Inc. Combination therapy of gamma-interferon and b cell specific antibodies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
JP4164871B2 (ja) 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
JP4424987B2 (ja) 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
CN1210307C (zh) 2001-11-16 2005-07-13 上海中信国健药业有限公司 抗cd20人源化单克隆抗体
EP1463524A4 (en) 2001-12-07 2005-02-09 Chiron Corp THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA
WO2003053926A1 (en) 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN100522999C (zh) 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2003070709A1 (en) 2002-02-20 2003-08-28 Ajinomoto Co.,Inc. Novel phenylalanine derivative
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP2005532276A (ja) * 2002-03-05 2005-10-27 ラモト アト テル−アヴィヴ ユニバーシティ リミテッド 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法
US7166441B2 (en) 2002-03-12 2007-01-23 Perseptive Biosystems Inc. Method and apparatus for the identification and quantification of biomolecules
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
AU2003235256A1 (en) 2002-04-19 2003-11-03 Kyowa Hakko Kogyo Co., Ltd. Phenylalanine derivative
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
PT1558648E (pt) 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
DE60322426D1 (cg-RX-API-DMAC7.html) 2002-12-16 2008-09-04 Genentech Inc
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
DE602004020061D1 (de) 2003-04-09 2009-04-30 Genentech Inc Behandlung von autoimmunkrankheit bei einem patienten mit unzureichendem ansprechen auf einen tnf-alpha-hemmer
WO2004091557A2 (en) 2003-04-09 2004-10-28 Hercules Incorporated Cationic, oxidized polysaccharides in conditioning applications
JP5416338B2 (ja) 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
BRPI0411276A (pt) 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
US7286240B2 (en) * 2003-06-19 2007-10-23 Zygo Corporation Compensation for geometric effects of beam misalignments in plane mirror interferometer metrology systems
WO2005011428A1 (en) 2003-07-25 2005-02-10 Bally Gaming International, Inc. Uniquely identifiable casino gaming chips
JP2007500844A (ja) 2003-07-29 2007-01-18 ジェネンテック・インコーポレーテッド ヒト抗ｃｄ２０抗体のアッセイとその用途
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
BRPI0412629A (pt) * 2003-08-29 2006-09-26 Genentech Inc método de tratamento de disfunção ocular em mamìferos
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
KR20060109494A (ko) 2003-12-19 2006-10-20 제넨테크, 인크. 자가면역 질환의 치료에 있어서 ｃｄ20의 검출
WO2005061542A2 (en) 2003-12-19 2005-07-07 Genentech, Inc. Detection of cd20 in transplant rejection
PL1706424T3 (pl) 2004-01-12 2010-04-30 Mentrik Biotech Llc Warianty regionu Fc
US7290012B2 (en) 2004-01-16 2007-10-30 International Business Machines Corporation Apparatus, system, and method for passing data between an extensible markup language document and a hierarchical database
WO2005113003A2 (en) 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
AU2005247303A1 (en) 2004-04-16 2005-12-08 Genentech, Inc. Treatment of polychondritis and mononeuritis multiplex with anti-CD20 antibodies
AU2005241431A1 (en) 2004-04-16 2005-11-17 Genentech, Inc. Assay for antibodies
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
BRPI0510224A (pt) 2004-05-05 2007-10-23 Genentech Inc métodos de prevenção de doença autoimunológica e artigo industrializado
US7514223B2 (en) 2004-05-15 2009-04-07 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
US7618627B2 (en) 2004-06-03 2009-11-17 The Regents Of The University Of California Method of increasing radiation sensitivity by inhibition of beta one integrin
CA2568336A1 (en) 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
ZA200610158B (en) 2004-06-04 2008-07-30 Genentech Inc Method for treating multiple sclerosis
KR101250127B1 (ko) 2004-07-09 2013-04-02 바이엘 파마 악티엔게젤샤프트 Ｂ-세포 림프종의 치료를 위한 방사성표지된 안티-ｃｄ20항체와의 병용요법
JP4501572B2 (ja) * 2004-07-20 2010-07-14 富士ゼロックス株式会社 書類管理装置および書類管理システム
AU2005267028A1 (en) 2004-07-22 2006-02-02 Genentech, Inc. Method of treating Sjogren's syndrome
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
WO2006029224A2 (en) 2004-09-08 2006-03-16 Genentech, Inc. Methods of using death receptor ligands and cd20 antibodies
EP1802660A2 (en) 2004-09-08 2007-07-04 Genentech, Inc. Methods of using death receptor ligands and cd20 antibodies
AU2005294666A1 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
TW200630106A (en) 2004-10-08 2006-09-01 Wyeth Corp Immunotherapy of autoimmune disorders
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
US20060134111A1 (en) 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
EP2290087A3 (en) 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
DOP2006000013A (es) 2005-01-13 2006-07-15 Genentech Inc Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
MX2007012197A (es) 2005-03-31 2007-11-21 Biomedics Inc Anticuerpo monoclonal anti-cd20.
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
BRPI0612972A2 (pt) 2005-04-22 2010-12-14 Genentech Inc mÉtodo para tratar doenÇa de alzheimer, mÉtodo para tratar demÊncia, artigo de fabricaÇço e usos de um anticorpo cd20
CA2609190A1 (en) 2005-05-18 2006-11-23 Biogen Idec Inc. Methods for treating fibrotic conditions
EP1902320B1 (en) 2005-05-20 2010-03-10 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
CA2609731A1 (en) 2005-05-24 2006-11-30 Avestha Gengraine Technologies Pvt Ltd. A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma
CN101282993A (zh) 2005-06-02 2008-10-08 阿斯利康公司 针对cd20的抗体和其用途
CA2608818A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
CN1290864C (zh) 2005-07-11 2006-12-20 中国人民解放军军事医学科学院生物工程研究所 一种抗cd20嵌合抗体
JP2009502936A (ja) 2005-07-25 2009-01-29 トルビオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２０特異的結合分子の単一投与量
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
US20070136826A1 (en) 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
NZ597251A (en) * 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
US20130004480A1 (en) 2006-07-04 2013-01-03 Paul Parren CD20 Binding Molecules for the Treatment of Copd
US20100000860A1 (en) 2006-09-08 2010-01-07 Tosoh Smd, Inc. Copper Sputtering Target With Fine Grain Size And High Electromigration Resistance And Methods Of Making the Same
CN101711286A (zh) 2007-04-02 2010-05-19 健泰科生物技术公司 预示类风湿性关节炎对b细胞拮抗剂的响应的生物学标志物
WO2008157282A1 (en) 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
CA3113365A1 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US8144978B2 (en) 2007-08-01 2012-03-27 Tandent Vision Science, Inc. System and method for identifying complex tokens in an image
RU2595383C2 (ru) 2007-09-05 2016-08-27 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия антителами анти-cd20 типа i и типа ii
GB0718684D0 (en) 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US20090110688A1 (en) 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
RU2498991C2 (ru) 2007-10-30 2013-11-20 Дженентек, Инк. Очистка антител с помощью катионообменной хроматографии
AU2008342956A1 (en) 2007-12-21 2009-07-09 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
ES2511844T3 (es) 2007-12-21 2014-10-23 F. Hoffmann-La Roche Ag Formulación de anticuerpo
CN101945890A (zh) 2007-12-21 2011-01-12 健泰科生物技术公司 抗cd20抗体的结晶
TWI500624B (zh) 2008-03-25 2015-09-21 Hoffmann La Roche 具有增進之抗體依賴型細胞毒性之第ii型抗－ｃｄ２０抗體之組合療法
US20090269339A1 (en) 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
KR20110086705A (ko) 2008-11-17 2011-07-29 제넨테크, 인크. 생리학적 조건 하에 거대분자의 응집을 감소시키는 방법 및 제제
AU2009313756B2 (en) 2008-11-17 2015-02-26 F. Hoffmann-La Roche Ag Method and formulation for reducing aggregation of a macromolecule under physiological conditions
MX353186B (es) * 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
KR20160061492A (ko) 2014-11-21 2016-06-01 삼성디스플레이 주식회사 휴대용 먼지 센서 및 이를 이용한 휴대전화

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5011013133; ＰＥＴＥＲＥＩＴ　ＨＥＬＡ-Ｆ: 'ＥＦＦＥＣＴＩＶＥ　ＳＵＰＰＲＥＳＳＩＯＮ　ＯＦ　ＣＥＲＥＢＲＯＳＰＩＮＡＬ　ＦＬＵＩＤ　Ｂ　ＣＥＬＬＳ　ＢＹ　ＲＩＴＵＸＩＭＡＢ　以下備考' ＡＲＣＨＩＶＥＳ　ＯＦ　ＮＥＵＲＯＬＯＧＹ Ｖ６２　Ｎ１０, 20051001, Ｐ１６４１-１６４２, ＡＭＥＲＩＣＡＮ　ＭＥＤＩＣＡＬ　ＡＳＳＯＣＩＡＴＩＯＮ *
JPN6014001647; Ｍｏｎｓｏｎ，Ｎ．Ｌ．　ｅｔ　ａｌ: 'Ｅｆｆｅｃｔ　ｏｆ　ｒｉｔｕｘｉｍａｂ　ｏｎ　ｔｈｅ　ｐｅｒｉｐｈｅｒａｌ　ｂｌｏｏｄ　ａｎｄ　ｃｅｒｅｂｒｏｓｐｉｎａｌ　ｆｌｕｉｄ　Ｂ　ｃｅｌｌｓ　ｉｎ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ｐｒｉｍａｒｙ' Ａｒｃｈｉｖｅｓ　ｏｆ　ｎｅｕｒｏｌｏｇｙ Ｖｏｌ．６２，　Ｎｏ．２, 2005, ｐ．２５８-６４ *
JPN6014001649; Ｈａｗｋｅｒ，Ｋ．　ｅｔ　ａｌ: 'Ｒｉｔｕｘｉｍａｂ　ｉｎ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ｐｒｉｍａｒｙ　ｐｒｏｇｒｅｓｓｉｖｅ　ｍｕｌｔｉｐｌｅ　ｓｃｌｅｒｏｓｉｓ：　ｒｅｓｕｌｔｓ　ｏｆ　ａ　ｒａｎｄｏｍｉｚｅｄ　ｄｏｕｂｌｅ-ｂｌ' Ａｎｎａｌｓ　ｏｆ　Ｎｅｕｒｏｌｏｇｙ Ｖｏｌ．６６，　Ｎｏ．４, 20090909, ｐ．４６０-４７１ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023123521A (ja) * 2015-10-06 2023-09-05 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法

Also Published As

Publication number Publication date
IL266189A (en) 2019-06-30
WO2010033587A2 (en) 2010-03-25
CN102215868B (zh) 2015-05-13
HUE067882T2 (hu) 2024-11-28
US20170029522A1 (en) 2017-02-02
AR073295A1 (es) 2010-10-28
US20240124603A1 (en) 2024-04-18
LT3747464T (lt) 2024-08-26
CL2011000553A1 (es) 2012-07-20
US20250171551A1 (en) 2025-05-29
HRP20241143T1 (hr) 2024-11-22
PT3747464T (pt) 2024-07-30
EP3747464A1 (en) 2020-12-09
CA2737074A1 (en) 2010-03-25
PL3747464T3 (pl) 2024-09-30
FI3747464T3 (fi) 2024-08-27
DK3095463T3 (da) 2020-11-16
JP2018127461A (ja) 2018-08-16
EP4364800A2 (en) 2024-05-08
PT3095463T (pt) 2020-11-03
DK3747464T3 (da) 2024-08-26
IL232222A0 (en) 2014-06-30
ES2830255T3 (es) 2021-06-03
EP3095463A3 (en) 2017-03-01
US20100158903A1 (en) 2010-06-24
BRPI0918604A2 (pt) 2015-12-01
EP3095463B1 (en) 2020-09-09
AR116859A2 (es) 2021-06-23
JP2020023507A (ja) 2020-02-13
US20140363431A1 (en) 2014-12-11
AU2009293363B2 (en) 2016-10-20
ZA201101854B (en) 2012-05-30
HRP20201740T1 (hr) 2020-12-25
TW201014605A (en) 2010-04-16
IL211710A0 (en) 2011-06-30
ES2988466T3 (es) 2024-11-20
SI3095463T1 (sl) 2021-01-29
IL232222B (en) 2019-05-30
LT3095463T (lt) 2020-11-25
US9994642B2 (en) 2018-06-12
US20120225070A1 (en) 2012-09-06
HK1210596A1 (en) 2016-04-29
CN104826107B (zh) 2018-10-19
US9683047B2 (en) 2017-06-20
US20220363772A1 (en) 2022-11-17
EP4364800A3 (en) 2024-08-07
EA201170465A1 (ru) 2011-10-31
CN104826107A (zh) 2015-08-12
US20210206869A1 (en) 2021-07-08
EP3747464B1 (en) 2024-06-26
EA034369B1 (ru) 2020-01-31
CA2737074C (en) 2021-04-13
JP2015007057A (ja) 2015-01-15
US20200157235A1 (en) 2020-05-21
AU2009293363A1 (en) 2010-03-25
EP2331132A2 (en) 2011-06-15
US20170349664A1 (en) 2017-12-07
JP2016147856A (ja) 2016-08-18
SI3747464T1 (sl) 2024-09-30
US20150307618A1 (en) 2015-10-29
HUE051206T2 (hu) 2021-03-01
US20190106500A1 (en) 2019-04-11
MX357820B (es) 2018-07-25
CN102215868A (zh) 2011-10-12
SG10201913368UA (en) 2020-02-27
SG10201406297TA (en) 2014-12-30
JP6306070B2 (ja) 2018-04-04
TW201438738A (zh) 2014-10-16
WO2010033587A3 (en) 2010-09-16
EP3095463A2 (en) 2016-11-23
MX2011002627A (es) 2011-05-25
PL3095463T3 (pl) 2021-02-08

Similar Documents

Publication Publication Date Title
US20250171551A1 (en) Methods for treating progressive multiple sclerosis
US20060051345A1 (en) Method for treating multiple sclerosis
JP2023123521A (ja) 多発性硬化症を治療するための方法
HK1210596B (zh) 用於治疗进行性多发性硬化的方法
CA2934069A1 (en) Method for treating multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141125

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20141222